Advanced Therapy Medicinal Products Market By Type (Gene Therapy, Cell Therapy, Tissue Engineering), By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Genetic Disorders), By End-User (Hospitals, Research Institutes, Biotechnology & Pharmaceutical Companies), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Advanced Therapy Medicinal Products Market was valued at USD 28.5 billion in 2023 and will surpass USD 85.1 billion by 2030; growing at a CAGR of 16.9% during 2024 - 2030. The Advanced Therapy Medicinal Products (ATMPs) market is rapidly growing, driven by the increasing demand for innovative treatments in areas such as oncology, cardiovascular diseases, neurological disorders, and genetic disorders. ATMPs include gene therapies, cell therapies, and tissue-engineered products, offering promising alternatives to traditional treatments. These therapies are designed to target the root cause of diseases, providing more personalized and effective healthcare solutions. The market is supported by advancements in biotechnology and pharmaceutical research, increasing regulatory approvals, and rising investment in R&D. As the healthcare landscape continues to evolve, ATMPs are poised to play a crucial role in revolutionizing the treatment of complex diseases, offering significant potential for both patients and healthcare providers. Gene Therapy Segment is Largest Owing to Expanding Applications The Gene Therapy segment continues to lead the Advanced Therapy Medicinal Products (ATMPs) market due to its breakthrough capabilities in treating genetic disorders by directly altering the genetic material inside cells. This therapy has gained traction as it offers the potential to cure diseases that were previously considered untreatable. With advancements in technologies like CRISPR and viral vectors, gene therapy is positioned for significant growth, especially in treating rare genetic disorders and certain types of cancer. The increasing demand for personalized medicine is further fueling the adoption of gene therapies across global healthcare systems. The largest application for gene therapy remains in the treatment of genetic disorders, such as sickle cell anemia, cystic fibrosis, and hemophilia. These diseases, which have long been difficult to treat through traditional methods, benefit immensely from the precision that gene therapy offers. Advances in gene-editing technologies like CRISPR, and growing regulatory acceptance, are accelerating gene therapy research and development, which is expected to continue its dominance in the coming years. Oncology Segment is Fastest Growing Owing to Rising Cancer Incidence The Oncology application for Advanced Therapy Medicinal Products (ATMPs) is the fastest-growing subsegment, driven by the increasing global burden of cancer. The rise in cancer cases, combined with the limitations of traditional cancer treatments like chemotherapy and radiation, is pushing the demand for innovative therapies. ATMPs, particularly in gene therapy and cell therapy, are proving to be valuable in targeting cancer cells with greater specificity, reducing side effects compared to traditional treatments. Immuno-oncology therapies, including CAR-T cells, are leading the way in revolutionizing cancer treatment, providing patients with new hope for long-term remission. The rapid development of immunotherapies, such as chimeric antigen receptor T-cell (CAR-T) therapies, is the key driver for the growth of oncology ATMPs. These therapies leverage the body’s own immune system to fight cancer, showing promising results in hematologic cancers like leukemia and lymphoma. As clinical trials advance and more drugs gain approval, oncology is expected to remain a key application area driving the expansion of ATMPs. Hospitals Segment is Largest End-User Due to Growing Treatment Demands The Hospitals segment is the largest end-user for Advanced Therapy Medicinal Products (ATMPs). Hospitals are primary centers for the administration of cutting-edge therapies such as gene and cell therapy, especially for critical conditions that require specialized care. With the increasing adoption of ATMPs in clinical settings, hospitals are becoming more equipped to handle these advanced treatments. The growing prevalence of chronic diseases, genetic disorders, and cancer, alongside hospitals' expanding capabilities in specialized treatments, is driving the adoption of these therapies in healthcare systems worldwide. Hospitals not only serve as the primary location for treatment but also as centers for innovation and clinical trials, contributing to the development of new therapies. Furthermore, hospitals are crucial in the post-treatment care and monitoring of patients receiving ATMPs, which further strengthens their role as the largest end-user of these therapies. North America is Largest Region Owing to Advanced Healthcare Infrastructure North America is the largest region in the Advanced Therapy Medicinal Products (ATMPs) market, primarily due to its advanced healthcare infrastructure, strong regulatory frameworks, and the high level of research and development investment from both the public and private sectors. The United States, in particular, is home to numerous biotechnology and pharmaceutical companies at the forefront of ATMP development. The country’s FDA has been proactively working towards streamlining the approval process for ATMPs, which has encouraged innovation and investment in this sector. Additionally, the high prevalence of chronic diseases and cancer in North America further contributes to the demand for innovative treatment options. North America’s dominance is also supported by collaborations between biotech companies, academic institutions, and healthcare providers, ensuring that the latest advancements in gene, cell, and tissue engineering therapies reach the market quickly. This dynamic ecosystem is expected to continue driving the market forward, with North America maintaining its leadership position. Leading Companies and Competitive Landscape The Advanced Therapy Medicinal Products (ATMPs) market is characterized by a highly competitive landscape, with key players including Gilead Sciences, Novartis AG, Pfizer Inc., Bluebird Bio, Inc., and Sangamo Therapeutics, Inc. These companies are not only involved in developing novel therapies but also in forging strategic partnerships and collaborations to enhance their research pipelines and accelerate the commercialization of advanced therapies. For instance, Gilead Sciences has made significant strides with its CAR-T cell therapies, while Novartis has led the charge in gene therapies for genetic disorders. The competitive environment is also marked by ongoing mergers and acquisitions (M&A), with companies acquiring smaller biotech firms that specialize in gene or cell therapy technologies. This trend is expected to continue as larger pharmaceutical firms seek to diversify their portfolios and gain a competitive edge in the rapidly evolving ATMP market. Furthermore, regulatory approval and reimbursement policies will play a crucial role in determining the success of these companies, as ATMPs often require substantial financial investment and long-term clinical trials before they can be commercially viable. Recent Developments: • Gilead Sciences received FDA approval for its gene therapy treatment aimed at chronic lymphocytic leukemia (CLL), marking a major milestone in oncology gene therapy. • Novartis AG announced the successful acquisition of a biotechnology firm specializing in cell-based immunotherapies, strengthening its position in the ATMP market. • Bluebird Bio launched its new gene therapy product for sickle cell anemia, representing a significant advancement in genetic disorder treatments. • Bayer AG recently entered into a partnership with a leading gene therapy company to accelerate the development of treatments for inherited retinal diseases. • Editas Medicine received FDA breakthrough therapy designation for its CRISPR-based gene editing treatment for genetic eye disorders, demonstrating the growing importance of gene therapies in the market. List of Leading Companies: • Gilead Sciences, Inc. • Novartis AG • Pfizer Inc. • Sangamo Therapeutics, Inc. • Bluebird Bio, Inc. • Bayer AG • Celgene Corporation (Bristol-Myers Squibb) • Boehringer Ingelheim GmbH • AbbVie Inc. • Orchard Therapeutics • Lonza Group • Kite Pharma (Gilead Sciences) • Medtronic PLC • Editas Medicine • Autolus Therapeutics Report Scope: Report Features Description Market Size (2023) USD 28.5 Billion Forecasted Value (2030) USD 85.1 Billion CAGR (2024 – 2030) 16.9% Base Year for Estimation 2023 Historic Year 2022 Forecast Period 2024 – 2030 Report Coverage Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered Advanced Therapy Medicinal Products Market By Type (Gene Therapy, Cell Therapy, Tissue Engineering), By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Genetic Disorders), By End-User (Hospitals, Research Institutes, Biotechnology & Pharmaceutical Companies) Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) Major Companies Gilead Sciences, Inc., Novartis AG, Pfizer Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Bayer AG, Celgene Corporation (Bristol-Myers Squibb), Boehringer Ingelheim GmbH, AbbVie Inc., Orchard Therapeutics, Lonza Group, Kite Pharma (Gilead Sciences), Medtronic PLC, Editas Medicine, Autolus Therapeutics Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements